Tetsuhiko Okuda1, Tomomi Higashide1, Mayumi Sakurai1, Yukako Fukuhira2, Hiroaki Kaneko2, Masatsugu Shimomura3, Kazuhisa Sugiyama1. 1. Department of Ophthalmology Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. 2. Research Laboratories III, Integrative Technology Research Institute, New Business Development Group, Teijin Limited, Tokyo, Japan. 3. Department of Bio- and Material Photonics, Faculty of Photonics Science and Technology, Chitose Institute of Science and Technology, Chitose, Japan.
Abstract
PURPOSE: A honeycomb-patterned film (HPF) prevents bleb scarring and mitomycin C (MMC)-related bleb avascularity in a rabbit model of filtration surgery. In this study, we examined whether a HPF-releasing paclitaxel (PTX) can prevent bleb avascularity without compromising filtration. METHODS: Filtration surgery was performed in one eye of rabbits. A 14-μm thick HPF made from poly(L-lactide-co-ε-caprolactone) was placed subconjunctivally over the filtration site with the honeycomb surface turned toward the subconjunctival Tenon tissue. The rabbits were divided into four groups (n = 5 each): 1, HPF with no drug; 2, HPF + PTX 50 μg; 3, HPF + 5 μg; 4, HPF + 0.5 μg. Intraocular pressure (IOP) measurements and bleb evaluations using ultrasound biomicroscopy were performed periodically for 4 weeks followed by histological examination. A longer follow-up study (12 weeks) was performed for group 4 (experiment 2; n = 8). RESULTS: Among all groups at the 4-week follow up, two blebs failed in group 1. The postoperative IOP decrease was significantly greater in PTX-treated eyes than in group 1. The bleb avascular area persisted for 4 weeks in groups 2 and 3. However, no avascular area was observed in groups 1 and 4 at 4 weeks postoperatively. Histology showed minimal fibrosis at the filtration site in all the PTX groups. In experiment 2, some blebs became flatter starting at 10 weeks after surgery. CONCLUSIONS: PTX released from HPF promoted bleb survival and IOP decrease. The lowest dose of PTX (0.5 μg) was effective at preventing bleb avascularity without compromising filtration.
PURPOSE: A honeycomb-patterned film (HPF) prevents bleb scarring and mitomycin C (MMC)-related bleb avascularity in a rabbit model of filtration surgery. In this study, we examined whether a HPF-releasing paclitaxel (PTX) can prevent bleb avascularity without compromising filtration. METHODS: Filtration surgery was performed in one eye of rabbits. A 14-μm thick HPF made from poly(L-lactide-co-ε-caprolactone) was placed subconjunctivally over the filtration site with the honeycomb surface turned toward the subconjunctival Tenon tissue. The rabbits were divided into four groups (n = 5 each): 1, HPF with no drug; 2, HPF + PTX 50 μg; 3, HPF + 5 μg; 4, HPF + 0.5 μg. Intraocular pressure (IOP) measurements and bleb evaluations using ultrasound biomicroscopy were performed periodically for 4 weeks followed by histological examination. A longer follow-up study (12 weeks) was performed for group 4 (experiment 2; n = 8). RESULTS: Among all groups at the 4-week follow up, two blebs failed in group 1. The postoperative IOP decrease was significantly greater in PTX-treated eyes than in group 1. The bleb avascular area persisted for 4 weeks in groups 2 and 3. However, no avascular area was observed in groups 1 and 4 at 4 weeks postoperatively. Histology showed minimal fibrosis at the filtration site in all the PTX groups. In experiment 2, some blebs became flatter starting at 10 weeks after surgery. CONCLUSIONS:PTX released from HPF promoted bleb survival and IOP decrease. The lowest dose of PTX (0.5 μg) was effective at preventing bleb avascularity without compromising filtration.
Entities:
Keywords:
avascular bleb; drug delivery; honeycomb-patterned film; trabeculectomy
Authors: Marian Löbler; Katrin Sternberg; Oliver Stachs; Reto Allemann; Niels Grabow; Anne Roock; Christine F Kreiner; Detlef Streufert; Axel T Neffe; Bui Duc Hanh; Andreas Lendlein; Klaus-Peter Schmitz; Rudolf Guthoff Journal: J Biomed Mater Res B Appl Biomater Date: 2011-03-22 Impact factor: 3.368
Authors: A W Heldman; L Cheng; G M Jenkins; P F Heller; D W Kim; M Ware; C Nater; R H Hruban; B Rezai; B S Abella; K E Bunge; J L Kinsella; S J Sollott; E G Lakatta; J A Brinker; W L Hunter; J P Froehlich Journal: Circulation Date: 2001-05-08 Impact factor: 29.690
Authors: E J Higginbotham; R K Stevens; D C Musch; K O Karp; P R Lichter; T J Bergstrom; G L Skuta Journal: Ophthalmology Date: 1996-04 Impact factor: 12.079